{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:43:11Z","timestamp":1785220991638,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11060-019-03273-1","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T16:04:19Z","timestamp":1566835459000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database"],"prefix":"10.1007","volume":"145","author":[{"given":"Kenichiro","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-5314","authenticated-orcid":false,"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,26]]},"reference":[{"issue":"6382","key":"3273_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350\u20131355","journal-title":"Science"},{"key":"3273_CR2","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J (2018) Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363:k4226","journal-title":"BMJ"},{"issue":"12","key":"3273_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728","journal-title":"JAMA Oncol"},{"key":"3273_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, G\u00f6ppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210\u2013225","journal-title":"Eur J Cancer"},{"issue":"10","key":"3273_CR5","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216\u20131222","journal-title":"JAMA Neurol"},{"key":"3273_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138","journal-title":"Eur J Cancer"},{"issue":"2","key":"3273_CR7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","volume":"28","author":"L Spain","year":"2017","unstructured":"Spain L, Walls G, Julve M, O'Meara K, Schmid T, Kalaitzaki E, Turajlic S, Gore M, Rees J, Larkin J (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28(2):377\u2013385","journal-title":"Ann Oncol"},{"issue":"1","key":"3273_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","volume":"18","author":"C Astaras","year":"2018","unstructured":"Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF (2018) Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep 18(1):3","journal-title":"Curr Neurol Neurosci Rep"},{"key":"3273_CR9","doi-asserted-by":"crossref","first-page":"175628641879986","DOI":"10.1177\/1756286418799864","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC (2018) Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord 11:1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"3273_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, Suijkerbuijk KPM, Azevedo S, Li H, Reshef D, Avila A, Reardon DA (2017) Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22(6):709\u2013718","journal-title":"Oncologist"},{"key":"3273_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG (2017) Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 82:128\u2013136","journal-title":"Eur J Cancer"},{"issue":"11","key":"3273_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127\u20131134","journal-title":"Neurology"},{"issue":"1","key":"3273_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7(1):134","journal-title":"J Immunother Cancer"},{"issue":"11","key":"3273_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/phar.2035","volume":"37","author":"AK Ali","year":"2017","unstructured":"Ali AK, Watson DE (2017) Pharmacovigilance assessment of immune-mediated reactions reported for checkpoint inhibitor cancer immunotherapies. Pharmacotherapy 37(11):1383\u20131390","journal-title":"Pharmacotherapy"},{"key":"3273_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1200\/JCO.2018.36.5_suppl.37","volume":"36","author":"CR Garcia","year":"2018","unstructured":"Garcia CR, Cox JN, Villano JL (2018) Myasthenia gravis and Guillain-Barr\u00e9 syndrome adverse events with immune checkpoint inhibitors. J Clin Oncol 36:37. \n                    https:\/\/doi.org\/10.1200\/JCO.2018.36.5_suppl.37","journal-title":"J Clin Oncol"},{"issue":"4","key":"3273_CR16","doi-asserted-by":"publisher","first-page":"E76","DOI":"10.3390\/diagnostics8040076","volume":"8","author":"TG Soldatos","year":"2018","unstructured":"Soldatos TG, Dimitrakopoulou-Strauss A, Larribere L, Hassel JC, Sachpekidis C (2018) Retrospective side effect profiling of the metastatic melanoma combination therapy ipilimumab-nivolumab using adverse event data. Diagnostics (Basel) 8(4):E76","journal-title":"Diagnostics (Basel)"},{"key":"3273_CR17","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","volume":"9","author":"K Nomura","year":"2015","unstructured":"Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, Anzai T, Hashiguchi M, Mochizuki M (2015) Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Des Dev Ther 9:3031\u20133041","journal-title":"Drug Des Dev Ther"},{"issue":"8","key":"3273_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"3273_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1365-2125.1999.00957.x","volume":"47","author":"EP Van Puijenbroek","year":"1999","unstructured":"Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG (1999) Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol 47(6):689\u2013693","journal-title":"Br J Clin Pharmacol"},{"issue":"34","key":"3273_CR20","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","volume":"35","author":"M Sznol","year":"2017","unstructured":"Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebb\u00e9 C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD (2017) Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 35(34):3815\u20133822","journal-title":"J Clin Oncol"},{"issue":"26","key":"3273_CR21","doi-asserted-by":"publisher","first-page":"e7325","DOI":"10.1097\/MD.0000000000007325","volume":"96","author":"C Hao","year":"2017","unstructured":"Hao C, Tian J, Liu H, Li F, Niu H, Zhu B (2017) Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 96(26):e7325","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"3273_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.13063","volume":"85","author":"MN Joshi","year":"2016","unstructured":"Joshi MN, Whitelaw BC, Palomar MT, Wu Y, Carroll PV (2016) Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf) 85(3):331\u2013339","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03273-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-019-03273-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03273-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T23:08:20Z","timestamp":1598310500000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-019-03273-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,26]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["3273"],"URL":"https:\/\/doi.org\/10.1007\/s11060-019-03273-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,26]]},"assertion":[{"value":"8 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}